Drug Profile
Tocilizumab biosimilar - Hetero Biopharma
Alternative Names: TociraLatest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Hetero Biopharma
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID-19 pneumonia
Most Recent Events
- 12 Feb 2022 Safety and efficacy data from a clinical trial in COVID-19 pneumonia presented at the 29th Conference on Retroviruses and Opportunistic Infections (ROI-2022)
- 12 Feb 2022 Hetero Biopharma completes enrolment in a clinical trial in COVID-19 pneumonia in India (IV, Infusion), before February 2022
- 06 Sep 2021 Registered for COVID-19 pneumonia in India (IV)